Our publication confirms the favorable outcome of APL-pCT following BC in one patient, despite the presence of the CHEK2 germline mutation (detected at BC diagnosis) and an unfavorable AML-pCT genetic abnormality, involving the deletion of chromosome 17p13. The gene discussed is CHEK2; the disease is breast cancer.